02:23 , May 18, 2019 |  BioCentury  |  Product Development

AAVs on the brink: Charting the clinical landscape of in vivo gene therapies

Gene therapy is finally teetering on the edge of becoming a drug development mainstay, with at least nine AAV-based therapies in Phase III or II/III testing. An analysis of the AAV therapies in the clinic...
00:00 , Apr 26, 2019 |  BC Extra  |  Company News

Management tracks: Canbridge, Averum, WindMIL

Cancer and rare disease company Canbridge Pharmaceuticals Inc. (Beijing, China) hired Glenn Hassan as CFO and CBO and Gerald Cox as chief development strategist and interim CMO. Hassan, who was director, cross border healthcare investment...
21:22 , Jan 31, 2019 |  BC Innovations  |  Emerging Company Profile

Apic: Dual-gene therapies

Apic Bio Inc.'s APB-101 is a dual-function gene therapy for AAT deficiency that silences the mutant AAT gene and augments wild-type AAT expression, which the company believes gives it greater efficacy and lower liver toxicity...
03:55 , Dec 14, 2018 |  BC Innovations  |  Product R&D

Gene therapy’s make or buy choice

Whether or not to bring manufacturing in-house for gene therapy companies is becoming a critical choice, as contract manufacturers struggle to keep up with demand. The trade-off for the upfront investment risk is control over...
18:27 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

Adverum Biotechnologies Inc. (NASDAQ:ADVM) will discontinue development of gene therapy ADVM-043 to treat α-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The company said that although ADVM-043 was well tolerated among six patients in the open-label, U.S....
14:45 , Nov 2, 2018 |  BC Extra  |  Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

Adverum Biotechnologies Inc. (NASDAQ:ADVM) sank $1.21 (27%) to $3.34 on Friday after it said it will discontinue development of gene therapy ADVM-043 to treat α-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The company said late Thursday...
22:35 , Oct 19, 2018 |  BC Extra  |  Company News

Management tracks: AbbVie, Adverum

AbbVie Inc. (NYSE:ABBV) said EVP and CFO William Chase will retire in mid-2019. Effective immediately, Chase becomes EVP of finance and administration until his retirement and VP and Controller Robert Michael will succeed Chase as...
22:32 , May 14, 2018 |  BC Extra  |  Company News

Management tracks: Complexa, Immatics

Fibrotic and inflammatory disease company Complexa Inc. (Berwyn, Pa.) hired Francisco Salva as president and CEO. He was co-founder and VP of operations at Acerta Pharma B.V. (Oss, Netherlands). Immunotherapy company Immatics Biotechnologies GmbH (Tuebingen,...
22:28 , May 7, 2018 |  BC Extra  |  Company News

Management tracks: Adverum, Evolus

Adverum Biotechnologies Inc. (NASDAQ:ADVM) said President and CEO Amber Salzman has stepped down. CFO and SVP Leone Patterson is acting as interim president and CEO while the gene therapy company searches for a successor. Additionally,...
03:28 , Jan 19, 2018 |  BC Innovations  |  Tools & Techniques

Synthetic expressions

Bringing synthetic biology to transcriptional regulation could catalyze a new generation of gene therapies that are more tunable, disease-specific and easy to deliver than the products dominating the field. The new constructs include synthetic promoters...